NVS

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Novartis AG - ADR

CEO
Employees
105794
Headquarters

Lichtstrasse 35
Basel, Basel Stadt 4056
Phone: 41613241111
https://www.novartis.com/

News

Ion Channel Modulators Market to Witness Huge Growth by 2031 - Pfizer Inc., Novartis AG, Zydus Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc.
Aug 09, 2024 06:20am

DataM Intelligence has published a new research report on "Ion Channel Modulators Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and


Source:OpenPR
APONTIS PHARMA: Profitable H1 2024 Growth in Single Pill Combos, Full-Year Forecast Upheld
Aug 09, 2024 05:36am

APONTIS PHARMA saw impressive revenue growth in H1 2024, driven by Single Pill combinations and a new partnership with Novartis. The company turned profitable and raised its forecast, aiming for further expansion. Jetzt den vollständigen Artikel lesen


Source:Wallstreet:Online
Game-changer for kidney disease: Novartis’ Fabhalta wins FDA approval in record time
Aug 09, 2024 02:57am

Novartis has reached a pivotal moment in the treatment of rare kidney diseases with the US Food and Drug Administration (FDA) granting accelerated approval for Fabhalta (iptacopan), a novel therapy designed to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). This rare, progressively debilitating condition affects the kidneys by attacking the glomeruli, the […]


Source:Business News Today
US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs
Aug 08, 2024 17:54pm

On Thursday, Viatris Inc . (NASDAQ: VTRS ) reported second-quarter revenues of $3.797 billion, marginally above the consensus of $3.777 billion, up ~2% on a divestiture-adjusted operational basis . Brands net sales reached $2.36 billion, reflecting strong growth in Greater China and the expansion of the company’s portfolio in Emerging Markets and JANZ, partially offset by unfavorable channel dynamics in North America and the impact of government price regulations in Japan and Australia. Related: Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs . Generic net sales of $1.42 billion reflect strong growth from new product … Full story available on Benzinga.com


Source:Benzinga
FDA Approves Expanded Use Of Novartis'' Rare Disease Drug Fabhalta For Kidney Disease
Aug 08, 2024 13:52pm

On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE: NVS ) Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. In December 2023, the FDA approved Fabhalta as the first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria . This indication is granted under accelerated approval based on the pre-specified interim analysis of the Phase 3 APPLAUSE-IgAN study, which measured a reduction in proteinuria at nine months compared to placebo. Whether Fabhalta slows kidney function decline in patients with IgAN has not been established. The continued approval of Fabhalta may be contingent upon verification and description of … Full story available on Benzinga.com


Source:Benzinga
Generic weight-loss drugs? They’re coming — eventually, executive says
Aug 08, 2024 12:48pm

Sandoz, the generics drugmaker spun off from Novartis, is going to get into making cheap versions of the wildly popular GLP-1 class of drugs to treat diabetes and weight loss. But it may take a while.


Source:MarketWatch
Novartis Gains FDA Approval for Innovative Kidney Drug
Aug 08, 2024 10:30am

Novartis (NVS) has released an update. Novartis AG has announced the FDA accelerated approval of Fabhalta (iptacopan) for reducing proteinuria in p…


Source:TipRanks
Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Aug 08, 2024 10:30am

Jason Tardio, Experienced Multiple Sclerosis Drug Commercialization Executive, Formerly with Novartis and Biogen, Appointed Chief Operating Officer and President Strengthened Board of Directors with Appointment of Simona Skerjanec, Senior Pharmaceutical Executive and Thought Leader…


Source:PR Newswire
FDA approves Novartis’ complement inhibitor Fabhalta for rare kidney disease
Aug 08, 2024 06:53am

Novartis received accelerated approval from the FDA for a treatment for IgA nephropathy, an autoimmune disease in which too many of an antibody build up in the kidney. The drug, known as iptacopan, is marketed as Fabhalta. It was first approved in December for a rare blood disorder called paroxysmal


Source:EIN News Pharmaceuticals
Novartis Receives FDA Accelerated Approval For Fabhalta As First Complement Inhibitor For IgAN
Aug 08, 2024 01:42am

BASEL (dpa-AFX) - Novartis (NVS) announced that the U.S. Food and Drug Administration has granted accelerated approval for Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduc…


Source:Finanz Nachrichten